March 16 (Reuters) - BioMarin Pharmaceutical will discontinue mid-stage trials of its bone disorder treatment after reports ...
Phase 3 study designed with total hip BMD primary endpoint assessed at 12 months, rather than at 24 months. EB613 single ...
Researchers are evaluating whether biologic therapies for severe asthma reduce the risk for osteoarthritis progression in ...
Understanding the type of arthritis, its causes, and management options is the first step toward living well with the ...
GLP-1 medications like Ozempic, Wegovy and Mounjaro have become something of a cultural lightning rod over the past few years ...
With Ascendis Pharma entering the achondroplasia space last month and BridgeBio on deck, BioMarin faces competition. Adding ...
A 3-month course of romosozumab followed by denosumab provides similar BMD gains to those seen with 12 months of romosozumab ...
For five years, everything went seamlessly, but in November 2025, Newton noticed that Kramer was extremely thirsty, ...
The checkered injury history of Reds starting pitcher Hunter Greene added another unwanted chapter when the club revealed ...
Cincinnati Reds starter Hunter Greene will have arthroscopic surgery to remove bone fragments from his right elbow Wednesday, ...
New platform connects patients with licensed providers offering sermorelin under medical supervision, supported by a growing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results